Ascendis Pharma Reports Q2 EPS of EUR 0.82, Revenue of EUR 158.05M

Ascendis Pharma reported Q2 EPS of EUR 0.82, beating last year's (EUR 2.21) and Q2 revenue of EUR 158.05M, up from EUR 36M last year. The company's President and CEO, Jan Mikkelsen, expects continued momentum as they aim to address unmet medical needs in endocrine rare diseases and other large indications.

Ascendis Pharma A/S (ASND) reported its second-quarter 2025 financial results, showing a quarterly adjusted loss of 64 cents per share, which was a significant improvement compared to the same period last year when the company reported an EPS of €-1.91 [1]. The mean expectation of fifteen analysts for the quarter was a loss of €1.25 per share, with Wall Street expecting results to range from €-1.77 to -79 cents per share [1].

Revenue for the second quarter of 2025 reached €158.05 million, marking a 339% increase from the same period last year, when revenue was €36.0 million [2]. This growth was primarily driven by the strong performance of YORVIPATH, which generated revenue of €103.0 million, and SKYTROFA, which brought in €50.7 million [2]. The company's President and CEO, Jan Mikkelsen, noted that the robust global uptake of YORVIPATH and the priority review of TransCon CNP by the U.S. FDA are key factors contributing to the company's financial transformation [2].

Despite the significant revenue growth, Ascendis Pharma reported a net loss of €38.9 million for the second quarter of 2025, compared to a net loss of €109.4 million in the same period last year [2]. This decrease in net loss was driven by an increase in commercial product revenue and a decrease in research and development costs. The company's cash and cash equivalents stood at €494 million as of June 30, 2025, compared to €560 million as of December 31, 2024 [2].

Mikkelsen expressed optimism about the company's future, stating that the continued momentum will enable Ascendis Pharma to address unmet medical needs in endocrine rare diseases and other large indications [2]. The company plans to submit a Marketing Authorisation Application (MAA) for TransCon CNP to the European Medicines Agency (EMA) during the third quarter of 2025 and expects to initiate a Phase 3 combination trial for TransCon CNP and TransCon hGH in the fourth quarter of 2025 [2].

Analysts have a positive outlook on Ascendis Pharma, with the current average analyst rating on the shares being "buy" and no "hold" or "sell" recommendations [1]. The median 12-month price target for Ascendis Pharma is $224.50, about 15.2% above its last closing price of $190.35 [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U009J:0-ascendis-pharma-a-s-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.nasdaq.com/press-release/ascendis-pharma-reports-second-quarter-2025-financial-results-2025-08-07